X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Press Statements

DuPont Brings Science-backed Quality and Innovation to Asia’s Pharmaceutical Industry at CPhI China 2020

Content Team by Content Team
14th December 2020
in Press Statements
DuPont Brings Science-backed Quality and Innovation to Asia's Pharmaceutical Industry at CPhI China 2020

DuPont Nutrition & Biosciences (DuPont) will use insights to help manufacturers evolve with the biggest trends in the Asia pharma industry, with highlights to the latest offerings at CPhI China 2020 from December 16–18. Attendees who visit DuPont booth E3D26 will get an exclusive look at solutions to many of the industry’s most pressing challenges, including taste-masking for pediatric medicines, pharmaceutical ingredients for acid reflux, and controlled release solutions that can significantly enhance manufacturing processes and much more.

DuPont has continuously supported its pharmaceutical customers with its vital expertise, and broad, unique portfolio that helps formulators succeed in manufacturing, regulatory, product design and beyond. As China’s pharmaceutical industry continues to expand in profitability and regulatory complexity, DuPont intends to show customers that it has the products and technical know-how to help them keep pace. 

Experts will be available to discuss the offerings which include:

  • Ensuring compliance among younger patients. No child likes the taste of medicine, which means taste-masking bitter active pharmaceutical ingredients (APIs) is of utmost importance in pediatric care. DuPont offers several solutions, including colloidal Avicel® microcrystalline cellulose (MCC), which is ideal for use in oral suspension; and ETHOCEL™ and Aquacoat®, two superior coating polymers that effectively mask unpleasant tastes.
  • Optimal ingredients for controlled release. METHOCEL™ DC2 is a cellulose ether that achieves superior process control with fewer production steps and less waste. With improved flow, faster and consistent tableting speeds, it greatly enhances overall production efficiency.
  • Sustainable ingredients that treat acid reflux. Protanal® is a tailored innovative solution highly aligned with market trends and can be used as an API in the treatment of acid reflux. Using a patented and environmentally friendly technology, this brown seaweed extract helps to enable enhanced performance.
  • Focus on quality beyond manufacturing. Given quality is paramount for our industry, DuPont will discuss its efforts to broaden its quality focus beyond manufacturing to an organizational priority. Efforts also include an extension of its renowned Avicel® to reduce technically unavoidable particles (TUPs).
  • A whole new range of innovative delivery forms for dietary supplements industry. We offer a vast range of functional ingredients that works well with nutritional ingredients to make a product that meets consumer demands – from clean label, plant-based, consumer-friendly capsules, great tasting gummies and smaller tablets for consumer convenience. Our SeaGel® vegetarian softgel technology outperforms its animal-based counterpart, imparting excellent thermal stability and implementing seamlessly into soft capsule equipment.

At the booth, attendees can attend mini talks and discuss with DuPont experts on how they can enable their goals in the pharma and dietary supplements space, including sharing of best practices for each ingredient, application expertise and regulatory knowledge tailored to the Asian market.

“All of these offerings represent our commitment to delivering strategic, high quality customer service to the Asia’s pharma industry,” explained Frank Zhao, Sales Leader, APAC, Pharma Solutions, DuPont Nutrition & Biosciences. “It’s a reflection of our global implementation of Big Q—a Quality culture. We believe our focus on quality will resonate with visitors at CPhI China, who will come away with practical solutions to create viable pharmaceutical products for this expanding market.”

About DuPont Nutrition & Biosciences

DuPont Nutrition & Biosciences applies expert science to advance market-driven, healthy and sustainable solutions for the food, beverage, dietary supplement and pharmaceutical industries. We also use cutting-edge biotechnology across a range of markets to advance bio-based solutions to meet the needs of a growing population, while protecting our environment for future generations. We are innovative solvers who help our customers turn challenges into high-value business opportunities.

About DuPont

DuPont is a global innovation leader with technology-based materials, ingredients and solutions that help transform industries and everyday life. Our employees apply diverse science and expertise to help customers advance their best ideas and deliver essential innovations in key markets including electronics, transportation, construction, water, health and wellness, food, and worker safety.

Previous Post

AstraZeneca and J&J COVID-19 Shots Crucial To Meet US Vaccination Goal

Next Post

Thermo Fisher Expands Clinical Supply Services in Europe

Related Posts

Avadel Pharmaceuticals Receives
Drug Development

Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

9th June 2025
ACHEMA
Middle East and South Asia

ACHEMA Middle East to Debut in Riyadh in 2026 Trade Show

9th May 2025
Press Statements

APM Steam Highlights Comprehensive HVAC Insulation Services for Biopharmaceutical and Pharmaceutical Facilities

19th April 2025
Americas

Thermo Fisher to acquire Solventum’s Purification & Filtration business for US$4.1bn

4th March 2025
Drug Development

Celonic Group Signs Long-Term Multi-Year Manufacturing Service Agreement with LINDIS Biotech for the Commercial Supply of Catumaxomab

4th March 2025
Drug Development

Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront

4th March 2025
Next Post
Thermo Fisher Scientific Launches Modular Closed Cell Processing System for Cell Therapy Manufacturing

Thermo Fisher Expands Clinical Supply Services in Europe

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In